MYDA Advisors LLC cut its position in shares of LianBio (NASDAQ:LIAN – Free Report) by 11.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 120,000 shares of the company’s stock after selling 15,000 shares during the quarter. MYDA Advisors LLC’s holdings in LianBio were worth $235,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of LIAN. Price T Rowe Associates Inc. MD increased its holdings in LianBio by 32.7% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 2,822,857 shares of the company’s stock valued at $5,618,000 after acquiring an additional 695,979 shares in the last quarter. Citigroup Inc. acquired a new position in LianBio in the 1st quarter valued at about $1,980,000. Renaissance Technologies LLC raised its position in shares of LianBio by 417.2% in the third quarter. Renaissance Technologies LLC now owns 315,000 shares of the company’s stock valued at $630,000 after buying an additional 254,100 shares during the last quarter. Affinity Asset Advisors LLC lifted its stake in shares of LianBio by 348.9% during the first quarter. Affinity Asset Advisors LLC now owns 325,000 shares of the company’s stock valued at $1,206,000 after buying an additional 252,594 shares during the period. Finally, Citadel Advisors LLC grew its stake in LianBio by 18.2% in the 2nd quarter. Citadel Advisors LLC now owns 837,173 shares of the company’s stock worth $1,809,000 after acquiring an additional 128,867 shares during the period. 74.85% of the stock is currently owned by hedge funds and other institutional investors.
LianBio Trading Up 3.7 %
Shares of LIAN opened at $1.69 on Friday. LianBio has a fifty-two week low of $1.07 and a fifty-two week high of $2.90. The stock has a fifty day moving average of $2.01 and a two-hundred day moving average of $2.09.
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.
- Five stocks we like better than LianBio
- How Investors Can Identify and Successfully Trade Gap-Up Stocks
- MarketBeat Week in Review – 9/4 – 9/8
- Insider Selling Explained: Can it Inform Your Investing Choices?
- The Best 5 Small Cap AI Companies to Buy Now
- What Does the Consumer Price Index Measure?
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.